Scarica l'app Stockscreener
4.73
3.05%
0.14
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXST Giù?
Forum
Previsione
Precedente Chiudi:
$4.59
Aprire:
$4.64
Volume 24 ore:
978.77K
Relative Volume:
1.23
Capitalizzazione di mercato:
$195.81M
Reddito:
$134.48M
Utile/perdita netta:
$-38.94M
Rapporto P/E:
-4.9612
EPS:
-0.9534
Flusso di cassa netto:
$-19.34M
1 W Prestazione:
-1.46%
1M Prestazione:
-21.17%
6M Prestazione:
-61.58%
1 anno Prestazione:
-65.90%
Intervallo 1D:
$4.59
$4.73
Intervallo di 1 settimana:
$4.56
$4.94
Portata 52W:
$4.48
$14.29
Rxsight Inc Stock (RXST) Company Profile
Nome
Rxsight Inc
Settore
Industria
Telefono
949-521-7822
Indirizzo
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
4.73 | 195.81M | 134.48M | -38.94M | -19.34M | -0.9534 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Iniziato | William Blair | Mkt Perform |
| 2025-07-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | Downgrade | Jefferies | Buy → Hold |
| 2025-07-09 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-07-09 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-07-09 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | Iniziato | Piper Sandler | Neutral |
| 2025-04-09 | Downgrade | UBS | Buy → Neutral |
| 2025-04-04 | Downgrade | JP Morgan | Overweight → Underweight |
| 2025-04-03 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-12-20 | Downgrade | Stifel | Buy → Hold |
| 2024-12-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Iniziato | UBS | Buy |
| 2024-10-29 | Iniziato | Jefferies | Buy |
| 2024-08-20 | Reiterato | Needham | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-05-07 | Reiterato | BTIG Research | Buy |
| 2023-12-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | Iniziato | Stifel | Buy |
| 2023-12-04 | Iniziato | Morgan Stanley | Overweight |
| 2023-04-13 | Iniziato | Oppenheimer | Outperform |
| 2022-12-12 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | Iniziato | Needham | Buy |
Mostra tutto
Rxsight Inc Borsa (RXST) Ultime notizie
Rxsight Inc (RXST) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RxSight (RXST) director receives 37,037 restricted stock units in equity grant - Stock Titan
RxSight (RXST) director awarded 37,037 RSUs in equity compensation grant - Stock Titan
RxSight (RXST) director Shweta Maniar receives 37,037 RSU award - Stock Titan
Tamara Fountain at RxSight (RXST) receives 37,037-share RSU award - Stock Titan
RxSight (RXST) director William J. Link granted 37,037-share stock award - Stock Titan
RxSight (RXST) director Corley Jesse Anderson granted 37,037 RSUs - Stock Titan
RxSight (RXST) director granted 30,864 RSUs vesting by next meeting - Stock Titan
RxSight (RXST) director receives 37,037 RSUs, now directly holds 85,183 shares - Stock Titan
RxSight (RXST) director receives 37,037 RSUs vesting by next stockholder meeting - Stock Titan
Rxsight Inc (RXST) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rxsight Inc (RXST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rxsight Inc (RXST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rxsight Inc (RXST) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rxsight Inc (RXST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rxsight Inc (RXST) Institutional Confidence - TradingKey
Rxsight Inc (RXST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
RxSight (RXST) investors re-elect board, approve pay and ratify Ernst & Young - Stock Titan
RxSight Inc Stock (US78419L1008): Valuation Focus After Strong Run In Eye Technology - AD HOC NEWS
Rxsight Inc (RXST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RxSight, Inc. Hits 52-Week Low of $4.58 Amidst 92.2% Decline - MarketsMojo
RxSight, Inc. Stock Plummets to New 52-Week Low of $4.49 - MarketsMojo
RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates - MSN
RxSight Inc. (RXST) Falters Near Support: Testing Key Levels After 1.96% DeclineDark Pool Sentiment - newsline.com
Understanding Momentum Shifts in (RXST) - Stock Traders Daily
RxSight, Inc. Hits 52-Week Low at $5.31 Amid Ongoing Struggles - MarketsMojo
RxSight, Inc. Hits 52-Week Low at USD 4.93 Amidst Ongoing Struggles - MarketsMojo
RxSight Inc. (RXST) Slides 3% as Stock Struggles Below Key Resistance at $5.03Put Wall - newsline.com
RxSight Inc. (RXST) Q1 2026 Earnings: EPS Miss Weighs on Shares Amid Operating ChallengesProfitability Analysis - newsline.com
RXST Technical Analysis & Stock Price Forecast - Intellectia AI
RxSight Inc stock (US78419L1008): Nasdaq-listed eye-care specialist in focus after recent price weak - AD HOC NEWS
RXST Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin; Stock DeclinesEarnings Call Highlights - newsline.com
RxSight Inc. (RXST) Slips 4.65% as Stock Challenges $5.06 Support LevelTICK Divergence - The Legal Advocate
RxSight Securities Lawsuit Advances After Court Denies Dismissal Bid - TipRanks
RXST Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing Ramp-UpEPS Growth Rate - The Legal Advocate
Midday Stock Roundup: TTM Drops on Investor Day - Orange County Business Journal
RxSight Must Litigate Investor Suit Over Eye Lens System Demand - Bloomberg Law News
RXST: Premium IOL penetration grows as competitive headwinds ease and commercial focus intensifies - TradingView
Avoiding Lag: Real-Time Signals in (RXST) Movement - Stock Traders Daily
RxSight Inc. Q1 2026 Earnings: EPS Misses Estimates Amid Operational HeadwindsOne-Time Loss Impact - Newser
RxSight Q1 2026 Earnings: EPS Misses Estimates by 32% as Operational Costs WeighEarnings Beat Streak - The Legal Advocate
RxSight stock gains ahead of Stifel meeting, investors wait for signs of turnaround - Bez Kabli
RxSight to present at Stifel 2026 Virtual Ophthalmology Forum on May 26 - Pluang
RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum - The Manila Times
RxSight management to appear at Stifel 2026 virtual eye forum May 26 - Stock Titan
RxSight stock (US78419L1008): Q1 revenue dip and share slide put growth story to the test - AD HOC NEWS
Tarsus, RxSight Fall Despite Growth Signals - Orange County Business Journal
RxSight stock (US78419L1008): FDA-linked growth and execution stay in focus - AD HOC NEWS
RxSight stock (US78419L1008): FDA-backed growth story stays in focus - AD HOC NEWS
Number of shareholders of RxSight, Inc. – NASDAQ:RXST - TradingView
Discipline and Rules-Based Execution in RXST Response - Stock Traders Daily
Rxsight Inc Azioni (RXST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):